Dapansutrile is primarily investigated for its anti-inflammatory properties, particularly through its action as a NLRP3 inflammasome inhibitor. This makes it a candidate for treating conditions driven by chronic inflammation. It has been studied in inflammatory diseases such as gout, where it helps reduce IL-1β release, a key mediator in inflammatory responses. Research also explores its potential in cardiovascular conditions, including heart failure, due to its ability to modulate inflammatory pathways involved in myocardial remodeling. Additionally, dapansutrile has been evaluated in neuroinflammatory disorders and autoimmune conditions, where controlling inflammasome activation is critical. Its oral bioavailability and targeted mechanism support its development as a therapeutic agent in diseases with unmet needs in inflammation control.